Zofenopril (also known as Zofenoprilum [Latin]) is an angiotensin converting enzyme (ACE) inhibitor with cardioprotective properties indicated for the treatment of hypertension.[1]
In small studies, zofenopril appeared significantly more effective than the older antihypertensives atenolol and enalapril, and was associated with less adverse effects.[2]
Tarka is the brand name of an oral antihypertensive medication that combines a slow release formulation of verapamil hydrochloride, a calcium channel blocker, and an immediate release formulation of trandolapril, an ACE inhibtor. The patent, held by Abbott Laboratories, expired on June 12, 2007.
Trandolapril is teratogenic and can cause birth defects and even death of the developing fetus. The highest risk to the fetus is during the second and third trimester. When pregnancy is detected, Trandolapril should be discontinued as soon as possible.
Trandolapril should not be administed to nursing mothers.
Patients also on diuretics may experience an excessive reduction of blood pressure after initiation of therapy with Trandolapril. Trandolapril can reduce potassium loss caused by thiazide diuretics, and increase serum potassium when used alone. Therefore hyperkalemia is a possible risk. Increased serum lithum levels can occur in patients who are also on lithium. For more information see angiotensin converting enzyme (ACE) inhibitors.
Trandolapril acts by competitive inhibition of Angiotensin Converting Enzyme (ACE), a key enzyme in the renin-angiotensin system (RAS pathway) which plays an important role in regulating blood pressure. See ACE inhibitors for more information.
Trandolapril acts by competitive inhibition of Angiotensin Converting Enzyme (ACE), a key enzyme in the renin-angiotensin system (RAS pathway) which plays an important role in regulating blood pressure. See ACE inhibitors for more information.
Trandolapril is a prodrug that is deesterified to trandolaprilat. It is believed to exert its antihypertensive effect through the renin-angiotensin-aldosterone system. Trandolapril has a half life of about 6 hours, and trandolaprilat has a half life of about 10. Trandolaprilat has about 8 times the activity of its parent drug. Approximately 1/3 of Trandolapril and its metabolites are excreted in the urine, and about 2/3 of Trandolapril and its metabolites are excreted in the feces. Serum protein binding of trandolapril is about 80%.
Trandolapril is an ACE inhibitor used to treat high blood pressure, it may also be used to treat other conditions. It is marketed by Abbott Laboratories with the brand name Mavik.
Temocapril (also known as Temocaprilum [Latin]; brand name Acecol) is an ACE inhibitor. It was not approved for use in the US.
^ Shohat J, Wittenberg C, Erman A, Rosenfeld J, Boner G (1999). “Acute and chronic effects of spirapril, alone or in combination with isradipine on kidney function and blood pressure in patients with reduced kidney function and hypertension.”. Scand J Urol Nephrol 33 (1): 57–62. doi:10.1080/003655999750016294. PMID 10100366.
^ Noble S, Sorkin E (1995). “Spirapril. A preliminary review of its pharmacology and therapeutic efficacy in the treatment of hypertension.”. Drugs 49 (5): 750–66. PMID 7601014.